{"title":"A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris","authors":"Kazuki Yatsuzuka MD, Masamoto Murakami MD, PhD","doi":"10.1002/cia2.12284","DOIUrl":null,"url":null,"abstract":"<p>This was the first case report in which an in-class IL-23 p19 inhibitor was switched (from guselkumab to tildrakizumab) during psoriasis vulgaris treatment. Four months after the switch, genital lesions, which were the patient's most significant complaint, improved with no subsequent worsening. We believe that our case will aid physicians who work in this problematic clinical setting.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 3","pages":"98-99"},"PeriodicalIF":1.1000,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12284","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 1
Abstract
This was the first case report in which an in-class IL-23 p19 inhibitor was switched (from guselkumab to tildrakizumab) during psoriasis vulgaris treatment. Four months after the switch, genital lesions, which were the patient's most significant complaint, improved with no subsequent worsening. We believe that our case will aid physicians who work in this problematic clinical setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
